CN101410114B - A3腺苷受体别构调节剂 - Google Patents

A3腺苷受体别构调节剂 Download PDF

Info

Publication number
CN101410114B
CN101410114B CN2007800106767A CN200780010676A CN101410114B CN 101410114 B CN101410114 B CN 101410114B CN 2007800106767 A CN2007800106767 A CN 2007800106767A CN 200780010676 A CN200780010676 A CN 200780010676A CN 101410114 B CN101410114 B CN 101410114B
Authority
CN
China
Prior art keywords
imidazo
quinoline
amine
phenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800106767A
Other languages
English (en)
Chinese (zh)
Other versions
CN101410114A (zh
Inventor
安尼可·高伯路斯
约翰尼斯·布鲁斯
A·P·伊泽曼
高占国
肯尼思·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leiden University
United States Department of Health and Human Services
Original Assignee
Leiden University
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiden University, United States Department of Health and Human Services filed Critical Leiden University
Publication of CN101410114A publication Critical patent/CN101410114A/zh
Application granted granted Critical
Publication of CN101410114B publication Critical patent/CN101410114B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CN2007800106767A 2006-01-26 2007-01-25 A3腺苷受体别构调节剂 Active CN101410114B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76214106P 2006-01-26 2006-01-26
US60/762,141 2006-01-26
PCT/US2007/001930 WO2007089507A1 (en) 2006-01-26 2007-01-25 A3 adenosine receptor allosteric modulators

Publications (2)

Publication Number Publication Date
CN101410114A CN101410114A (zh) 2009-04-15
CN101410114B true CN101410114B (zh) 2012-07-04

Family

ID=38116104

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800106767A Active CN101410114B (zh) 2006-01-26 2007-01-25 A3腺苷受体别构调节剂

Country Status (10)

Country Link
US (2) US8420664B2 (cg-RX-API-DMAC7.html)
EP (1) EP1983990B1 (cg-RX-API-DMAC7.html)
JP (2) JP5414277B2 (cg-RX-API-DMAC7.html)
KR (1) KR101383228B1 (cg-RX-API-DMAC7.html)
CN (1) CN101410114B (cg-RX-API-DMAC7.html)
AT (1) ATE502640T1 (cg-RX-API-DMAC7.html)
DE (1) DE602007013359D1 (cg-RX-API-DMAC7.html)
DK (1) DK1983990T3 (cg-RX-API-DMAC7.html)
ES (1) ES2360632T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007089507A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US7906518B2 (en) * 2006-06-27 2011-03-15 Cbt Development Limited Therapeutic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
US20110144156A1 (en) * 2008-08-19 2011-06-16 Universiteit Leiden A3 adenosine receptor allosteric modulators
WO2010134067A1 (en) * 2009-05-17 2010-11-25 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
MX378538B (es) * 2012-08-09 2025-03-10 Can Fite Biopharma Ltd Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual.
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
EP4499641A1 (en) * 2022-03-29 2025-02-05 The United States of America, as represented by the Secretary, Department of Health and Human Services A3 adenosine receptor positive allosteric modulators
WO2024014851A1 (ko) * 2022-07-12 2024-01-18 주식회사 넥스트젠바이오사이언스 Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물
IL300132A (en) * 2023-01-23 2024-08-01 Can Fite Biopharma Ltd Pancreatic cancer treatment
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007566A (ko) 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
KR20010030891A (ko) * 1997-10-03 2001-04-16 마크로메드 인코퍼레이션 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체
WO2002062801A1 (en) * 2001-02-05 2002-08-15 Otsuka Pharmaceutical Factory, Inc. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
US20040137477A1 (en) * 2002-10-22 2004-07-15 Can-Fite Biopharma, Ltd. A3AR as a marker for a diseased state
EP1699459B1 (en) 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif-1介导的病症
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAHARAV EE ET AL.Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.《JOURNAL OF RHEUMATOLOGY》._,2005,第32卷(第3期),第469页. *
FISHMAN P ET AL.Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.《ANTICANCER RESEARCH》._,2003,第23卷(第34期),第2077页. *
GAO,ZHAN-GUO ET AL.Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives.《MOLECULAR PHARMACOLOGY》._,2002,第62卷(第1期),第82、88页. *

Also Published As

Publication number Publication date
JP2013253108A (ja) 2013-12-19
DK1983990T3 (da) 2011-07-11
JP2009524668A (ja) 2009-07-02
WO2007089507A1 (en) 2007-08-09
US20090054476A1 (en) 2009-02-26
EP1983990A1 (en) 2008-10-29
JP5414277B2 (ja) 2014-02-12
KR101383228B1 (ko) 2014-04-09
US8420664B2 (en) 2013-04-16
US9326978B2 (en) 2016-05-03
ATE502640T1 (de) 2011-04-15
DE602007013359D1 (de) 2011-05-05
KR20080099855A (ko) 2008-11-13
US20130197025A1 (en) 2013-08-01
CN101410114A (zh) 2009-04-15
ES2360632T3 (es) 2011-06-07
EP1983990B1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
JP5414277B2 (ja) A3アデノシンレセプタ・アロステリックモジュレータ
CN110003204B (zh) 一种bet蛋白抑制剂、其制备方法及用途
US5990146A (en) Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US11466010B2 (en) Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof
JP5769199B2 (ja) ピラゾロピリミジンjak阻害剤化合物と方法
WO2024008129A1 (zh) 作为kat6抑制剂的化合物
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
TW200424206A (en) Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases
JP2019503389A (ja) Pde1阻害剤
UA111739C2 (uk) Імідазопіридазини як інгібітори аkt-кінази
CN111386114A (zh) 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
CN116997339A (zh) 作为治疗剂的cGAS活性抑制剂
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
CN108349974A (zh) 一种取代的吡啶酰胺类化合物及其应用
TW202332439A (zh) p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
JP2023544173A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
JP7092742B2 (ja) ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
ES2422872T3 (es) Moduladores alostéricos del receptor de adenosina A3
CN112592345B (zh) 一种三氮唑并吡嗪类化合物及其用途
JP2008526817A (ja) 新規のピロロジヒドロイソキノリン
JP2008517065A (ja) Brca2−rad51相互作用の破壊のための組成物及び方法
US20230132035A1 (en) Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof
JP2002201172A (ja) ベンズアミド誘導体及びその用途
WO2014082230A1 (zh) 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant